2026-02-06

press FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs The FDA announced plans to restrict non-FDA-approved GLP-1 active pharmaceutical ingredients used in compounded drugs marketed by companies like Hims & Hers, citing concerns over unverified quality, safety, and efficacy. The agency also warned against misleading claims in advertising, stating that compounded products cannot be presented as generics or clinically proven alternatives to FDA-approved drugs. Read more →